Futu News reported on March 27 that$DIAGENS-B (02526.HK)$The stock surged 90.3% in the gray market, trading at HKD 188.4. With each lot consisting of 50 shares and excluding transaction fees, a single lot yields a profit of HKD 4,470.
Source of market information: Futu Securities
Company Overview
De Shi is a medical device company focused on the development of medical imaging products and services. It has developed a diversified portfolio, including six medical imaging software products (one core product in the registration stage, AI AutoVision®, one commercialized product, AutoVision®, and four other medical imaging software candidates in the preclinical stage), three commercialized medical devices, four major reagents and consumables, and two technology-licensed products.
According to Frost & Sullivan, the company ranks first in China's chromosome karyotyping analysis sector based on sales revenue for 2024, with a market share of 30.6%. Its leading position is built on an outstanding track record in technological research and commercialization, including the success of its proprietary computer-aided chromosome analysis software, AutoVision®.
The core competitive advantage of its flagship product AI AutoVision® lies in the company’s self-developed iMedImage® medical imaging foundational model. As of the latest practicable date, it effectively supports 19 types of medical imaging modalities (such as chromosomes, CT, MRI, ultrasound, and pathology), covering more than 90% of clinical medical imaging scenarios, including reproductive health, hematologic malignancies, and other clinical applications.
Financial Overview
De Shi's revenue increased by 33.1% from RMB 52.8 million in 2023 to RMB 70.4 million in 2024, primarily due to income generated from technology licensing in 2024. For 2023 and 2024, as well as the nine months ended September 30, 2024, and September 30, 2025, the company’s gross profits were RMB 37.5 million, RMB 46.1 million, RMB 8.4 million, and RMB 84.7 million, respectively; during the same periods, the gross profit margins were 71.0%, 65.5%, 42.9%, and 75.9%, respectively.
Futu's grey market platform is stable and supports rapid order placement with market orders. Over 850,000 people have used Futu for subscribing to new shares, gaining an edge in the grey market, and executing trades faster than others.Come and experience it now >>
Editor/Deng